Allergan Unveils Spotlyte™, A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments


DUBLIN, /PRNewswire/ -- Allergan,plc (NYSE: AGN) today announced the launch of Spotlyte™ - an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines. Through well-researched content, product reviews and insider profiles, together with the latest beauty news and trends, the site functions as a holistic and informative lens into these worlds. Beyond the editorial, Spotlyte will provide access to a team of trained specialists ready to offer real-time support and chat directly with anyone considering medical aesthetic treatments, as well as help connect readers to local licensed providers.

Led by Alexandra Wilkis Wilson, co-founder of Gilt Groupe® and Glamsquad®, and appointed senior vice president of Consumer Strategy and Innovation at Allergan, Spotlyte is the first venture from the new Allergan-owned digital ventures unit, Project Moonwalker™. Dedicated to creating consumer facing businesses that unlock opportunities in the medical aesthetics category, Project Moonwalker will serve as a launchpad for new innovations that capitalize on a growing market.

"We have a unique position as industry leaders to identify emerging trends in real time and change the way that consumers engage with medical aesthetics," said Alexandra Wilkis Wilson. "I have spent most of my career focused on the consumer while creating powerful brands at the intersection of technology and lifestyle. The core goal of Project Moonwalker is to enable information flow and access. Spotlyte is the first step in changing how consumers can become better educated on medical aesthetics."

Consumers seek more information and don't always know where to go or who to trust. There are over 65 million Americans considering a variety of medical aesthetic treatments (from facial injectables to body contouring and breast implants) with approximately 30% citing lack of information as the top barrier to conversion. Allergan sees a huge opportunity to propel the aesthetics market forward by going direct to consumers.

"As the market leader in medical aesthetics, we have the opportunity and the responsibility to properly educate consumers and mainstream the conversation around aesthetic treatments. We want to create an open dialogue by incorporating medical aesthetics into the overall aesthetics conversation," said Brent Saunders, CEO of Allergan. "We believe the medical aesthetics market will double in 5-7 years."

The site is brand agnostic, with the goal of educating consumers and providing well researched and accurate information on medical aesthetics. For those who are curious or want to learn more, the on-site chat feature connects consumers to a specialist who will offer information and help make connections to local licensed providers.

For the latest news or more information, visit or follow the site on Instagram @Spotlyte.

All trademarks are the property of their respective owners.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.


Daphne Karydas
(862) 261-8006

Karina Calzadilla
(862) 261-7328

Amy Rose
(862) 289-3072

Amanda Rosenberg
(917) 415-2726

View original content to download multimedia:

SOURCE Allergan plc

Company Codes: NYSE:AGN

Back to news